Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Population-Based Analysis of Outcomes in Acute Myeloid Leukemia from a Provincial Cancer Registry and the Canadian Cancer Registry: A Population-Based Retrospective Cohort Study

Yaqeen Abduallah, Neelan Sriranjan, Kristjan Paulson, Brett L. Houston

Blood (2024) 144 (Supplement 1): 5959.

https://doi.org/10.1182/blood-2024-209461

Published: 2024

Journal Articles

Canadian Real-World Data for Acute Myeloid Leukemia Chemotherapy-Ineligible Patients on Venetoclax: An Interim Analysis from the Prospective Liven Study

Kristjan Paulson, Thomas Dunne, Lalit Saini, Nicole B. Laferriere, Michelle Geddes, Stephanie Desilets, David Sanford, Leanne Genge, Paola Lembo, Pierre-Andre Fournier, Brian Leber

Blood (2024) 144 (Supplement 1): 6069.

https://doi.org/10.1182/blood-2024-203473

Published: 2024

Journal Articles

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Irwin Walker, Uday Deotare, Mohamed Elemary, Mahmoud Elsawy, Genevieve Gallagher, David Kliman, Tony Panzarella, Nada Hamad, Kirk R. Schultz, Jan Storek, Kristjan Paulson

Blood (2024) 144 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2024-198798

Published: 2024

Journal Articles

Comparison of Prophylactic and Therapeutic Platelet Transfusion Strategies in Manitoba: A Retrospective Cohort Study

Andrea Soriano, Brett L. Houston, Neelan Sriranjan, Emily K. Rimmer, Donald Stuart Houston, Ryan Zarychanski, Kristjan Paulson, Olawale Ayilara, Tyler Moore

Blood (2024) 144 (Supplement 1): 7311.

https://doi.org/10.1182/blood-2024-204178

Published: 2024

Journal Articles

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12317–12318.

https://doi.org/10.1182/blood-2022-170652

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12315–12316.

https://doi.org/10.1182/blood-2022-170553

Published: 2022

Journal Articles

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Anna R. Blankstein, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Emily Rimmer, Donald S. Houston, Sylvain Lother, Asher Mendelson, Allan Garland, Ryan Zarychanski, Annette E. Hay, Rena Buckstein, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11656–11657.

https://doi.org/10.1182/blood-2022-164450

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Anna R. Blankstein, Neelan Sriranjan, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 6092–6093.

https://doi.org/10.1182/blood-2022-170961

Published: 2022

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Neelan Sriranjan, Anna R. Blankstein, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11632–11633.

https://doi.org/10.1182/blood-2022-171047

Published: 2022

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Characteristics of Hepatic Veno-Occlusive Disease from the Cell Therapy Transplant Canada Registry: A Retrospective Observational Study

Kevin Brown, MD BA, Kristjan Paulson, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-142237

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Dennis Dong Hwan Kim, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2019) 134 (Supplement_1): 1644.

https://doi.org/10.1182/blood-2019-128283

Published: 2019

Journal Articles

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Dennis Dong Hwan Kim, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, Stephen Couban, MDBSc, Robert Delage, MD, Anargyros Xenocostas, MD, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2018) 132 (Supplement 1): 787.

https://doi.org/10.1182/blood-2018-99-114656

Published: 2018

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

Craig Speziali, MD MSc, FRCPC, Andrew Daly, MD FRCPC, Mohamed Abuhaleeqa, MD, Janet Nitta, Yasser Abou Mourad, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kristjan Paulson, MD FRCPC

Blood (2016) 128 (22): 663.

https://doi.org/10.1182/blood.V128.22.663.663

Published: 2016

NARROW

Population-Based Analysis of Outcomes in Acute Myeloid Leukemia from a Provincial Cancer Registry and the Canadian Cancer Registry: A Population-Based Retrospective Cohort Study

Canadian Real-World Data for Acute Myeloid Leukemia Chemotherapy-Ineligible Patients on Venetoclax: An Interim Analysis from the Prospective Liven Study

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Comparison of Prophylactic and Therapeutic Platelet Transfusion Strategies in Manitoba: A Retrospective Cohort Study

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Characteristics of Hepatic Veno-Occlusive Disease from the Cell Therapy Transplant Canada Registry: A Retrospective Observational Study

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Provincial Disparities in Access to Allogeneic Transplant in Canada

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only